Bioventus Inc. delivers clinically proven, cost-effective products which help people heal quickly and safely. It includes offerings for osteoarthritis, surgical and non-surgical bone healing. Bioventus Inc. is based in DURHAM, N.C.
| Revenue (Most Recent Fiscal Year) | $568.09M |
| Net Income (Most Recent Fiscal Year) | $22.73M |
| PE Ratio (Current Year Earnings Estimate) | 11.80 |
| PE Ratio (Trailing 12 Months) | 13.19 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.31 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.25 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 7.03 |
| Pre-Tax Margin (Trailing 12 Months) | 4.53% |
| Net Margin (Trailing 12 Months) | 4.00% |
| Return on Equity (Trailing 12 Months) | 28.88% |
| Return on Assets (Trailing 12 Months) | 8.53% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.19 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.22 |
| Inventory Turnover (Trailing 12 Months) | 1.95 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.76 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.24 |
| Earnings per Share (Most Recent Fiscal Year) | $0.68 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.33 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 83.15M |
| Free Float | 55.71M |
| Market Capitalization | $745.90M |
| Average Volume (Last 20 Days) | 0.47M |
| Beta (Past 60 Months) | 0.70 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 33.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 62.94% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |